BMS growth driver Camzyos fails in heart disease trial, denting expansion opportunity
Camzyos came up short in a phase 3 trial weighing its use in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). In 2022, the drug won FDA approval to treat certain patients with obstructive HCM.
Camzyos came up short in a phase 3 trial weighing its use in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). In 2022, the drug won FDA approval to treat certain patients with obstructive HCM.
